留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

中国肾移植受者免疫抑制治疗指南(2016版)

中华医学会器官移植学分会 中国医师协会器官移植医师分会

中华医学会器官移植学分会, 中国医师协会器官移植医师分会. 中国肾移植受者免疫抑制治疗指南(2016版)[J]. 器官移植, 2016, 7(5): 327-331. doi: 10.3969/j.issn.1674-7445.2016.05.001
引用本文: 中华医学会器官移植学分会, 中国医师协会器官移植医师分会. 中国肾移植受者免疫抑制治疗指南(2016版)[J]. 器官移植, 2016, 7(5): 327-331. doi: 10.3969/j.issn.1674-7445.2016.05.001
Guideline on immunosuppressive therapy of recipients with renal transplantation in China(2016 edition)[J]. ORGAN TRANSPLANTATION, 2016, 7(5): 327-331. doi: 10.3969/j.issn.1674-7445.2016.05.001
Citation: Guideline on immunosuppressive therapy of recipients with renal transplantation in China(2016 edition)[J]. ORGAN TRANSPLANTATION, 2016, 7(5): 327-331. doi: 10.3969/j.issn.1674-7445.2016.05.001

中国肾移植受者免疫抑制治疗指南(2016版)

doi: 10.3969/j.issn.1674-7445.2016.05.001
基金项目: 

国家自然科学基金 81370578

国家自然科学基金 81570680

详细信息
  • 中图分类号: R617, R392.4

Guideline on immunosuppressive therapy of recipients with renal transplantation in China(2016 edition)

  • 摘要: 为提高临床医师对肾移植受者免疫抑制治疗的认识, 规范国内肾移植受者管理, 帮助医师在肾移植临床实践中做出合理决策, 我们组织专家制订了《中国肾移植受者免疫抑制治疗指南(2016版)》。该指南以《2009版改善全球肾病预后组织(KDIGO)肾移植受者管理指南》为主要参考, 结合我国的临床实践经验, 希望能为相关临床科室提供工作指引。

     

  • [1] Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey [J]. Lancet, 2012, 379 (9818): 815-822. doi: 10.1016/S0140-6736(12)60033-6
    [2] 王汀, 江金财, 俞志勇, 等.2013中国器官移植大会会议纪要[J/CD].中华移植杂志(电子版), 2014, 8(1): 42-6. http://www.doc88.com/p-9691853876929.html

    Wang T, Jiang JC, Yu ZY, et al. Organ transplantation conference in 2013 [J/CD]. Chin J Transplant (Electr Edit), 2014, 8(1): 42-6. http://www.doc88.com/p-9691853876929.html
    [3] Hammond EB, Taber DJ, Weimert NA, et al. Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation [J]. Clin Transplant, 2010, 24 (1): 40-7. doi: 10.1111/ctr.2010.24.issue-1
    [4] Ji SM, Li LS, Cheng Z, et al. A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience [J]. Transplant Proc, 2007, 39 (5): 1396-1401. doi: 10.1016/j.transproceed.2006.11.016
    [5] Kidney Disease: Improving Global Outcomes(KDIGO)Transplant Work Group.KDIGO clinical practice guideline for the care of kidney transplant recipients [J]. Am J Transplant, 2009, 9 (Suppl3): S1-S155. http://www.kdigo.org/clinical_practice_guidelines/pdf/KITxpGL_SupplementaryTables.pdf
    [6] Ekberg H, van Gelder T, Kaplan B, et al.Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation [J]. Transplantation, 2011, 92 (1): 82-87. doi: 10.1097/TP.0b013e31821fad06
    [7] Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation[ J]. N Engl J Med, 2007, 357 (25): 2562-2575. doi: 10.1056/NEJMoa067411
    [8] Ekbal NJ, Holt DW, Macphee IA. Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients [J]. Pharmacogenomics, 2008, 9 (5): 585-596. doi: 10.2217/14622416.9.5.585
    [9] Utecht KN, Hiles JJ, Kolear J. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors [J]. Am J Health Syst Pharm, 2006, 63 (23): 2340-2348. doi: 10.2146/ajhp060080
    [10] Lionaki S, Panagiotellis K, Iniotaki A, et al. Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation [J]. Clin Dev Immunol, 2013: 849835. http://www.ncbi.nlm.nih.gov/pubmed/24348683
    [11] WiebeC, GibsnIW, Blydt-HansnTD, etal. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant [J]. Am J Transplant, 2012, 12 (5): 1157-1167. doi: 10.1111/j.1600-6143.2012.04013.x
    [12] Vasconcellos LM, Schachter AD, Zheng XX, et al. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts [J]. Transplantation, 1998, 66 (5): 562-566. doi: 10.1097/00007890-199809150-00002
    [13] Girlanda R, Kirk AD. Frontiers in nephrology: immune tolerance to allografts in humans[ J]. J Am Soc Nephrol, 2007, 18 (8): 2242-2251. doi: 10.1681/ASN.2007020180
    [14] Laftavi MR, Sharma R, Feng L, et al. Induction therapy in renal transplant recipients: a review [J]. Immunol Invest, 2014, 43 (8): 790-806. doi: 10.3109/08820139.2014.914326
  • 加载中
计量
  • 文章访问数:  171
  • HTML全文浏览量:  84
  • PDF下载量:  32
  • 被引次数: 0
出版历程
  • 收稿日期:  2016-05-25
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2016-09-15

目录

    /

    返回文章
    返回